<p><sup>a</sup>Data presented represents the magnitude of vessel relaxation in response to the top concentration of rucaparib tested, except A5, where the second highest concentration is summarised.</p><p><sup>b</sup>Vessel section B1 was constricted with PE as the ‘A’ vessels; B2 contracted spontaneously, so is not summarized in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0118187#pone.0118187.t001" target="_blank">Table 1</a>.</p><p>Summary of rucaparib activity in PE-constricted human tumor-associated vasculature.</p
<p>Fig 7A. Images represent the change in capillary width induced by 10 ng/ml rBmAsnRS and 10 ng/ml ...
Objective: An integrated analysis was undertaken to characterize the antitumor activity and safet...
Contains fulltext : 81190.pdf (publisher's version ) (Closed access)Angiogenesis, ...
<p>Panels A and B; blockade of specific P2 receptor subtypes P2X<sub>4</sub>, P2X<sub>7</sub> and P2...
<div><p>Therapeutic inhibition of poly(ADP-ribose) polymerase (PARP), as monotherapy or to supplemen...
<p>Panel A; rucaparib (closed squares), nicotinamide (open squares) and ML-9 (open triangles) inhibi...
Therapeutic inhibition of poly(ADP-ribose) polymerase (PARP), as monotherapy or to supplement the po...
Therapeutic inhibition of poly(ADP-ribose) polymerase (PARP), as monotherapy or to sup-plement the p...
Background This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and o...
Anti-vascular cancer therapy is based on experimental evidence that the growth of solid tumours reli...
PURPOSE: Combretastatin A-4 disodium phosphate (CA4P) is a promising vascular disrupting agent (VDA)...
Contains fulltext : 110167.pdf (publisher's version ) (Open Access)BACKGROUND: Rad...
<p>Values are mean ± SD (n = 6). (A) Pe+/−SC26196 in aortae; (B) Pe+/−SC26196 in mesenteric arteries...
<p>Panel A; broad-spectrum antagonism of P2 receptors using suramin (inverted open triangles) abroga...
Objectives: Over the past few years, ruthenium has been under attention for development of organomet...
<p>Fig 7A. Images represent the change in capillary width induced by 10 ng/ml rBmAsnRS and 10 ng/ml ...
Objective: An integrated analysis was undertaken to characterize the antitumor activity and safet...
Contains fulltext : 81190.pdf (publisher's version ) (Closed access)Angiogenesis, ...
<p>Panels A and B; blockade of specific P2 receptor subtypes P2X<sub>4</sub>, P2X<sub>7</sub> and P2...
<div><p>Therapeutic inhibition of poly(ADP-ribose) polymerase (PARP), as monotherapy or to supplemen...
<p>Panel A; rucaparib (closed squares), nicotinamide (open squares) and ML-9 (open triangles) inhibi...
Therapeutic inhibition of poly(ADP-ribose) polymerase (PARP), as monotherapy or to supplement the po...
Therapeutic inhibition of poly(ADP-ribose) polymerase (PARP), as monotherapy or to sup-plement the p...
Background This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and o...
Anti-vascular cancer therapy is based on experimental evidence that the growth of solid tumours reli...
PURPOSE: Combretastatin A-4 disodium phosphate (CA4P) is a promising vascular disrupting agent (VDA)...
Contains fulltext : 110167.pdf (publisher's version ) (Open Access)BACKGROUND: Rad...
<p>Values are mean ± SD (n = 6). (A) Pe+/−SC26196 in aortae; (B) Pe+/−SC26196 in mesenteric arteries...
<p>Panel A; broad-spectrum antagonism of P2 receptors using suramin (inverted open triangles) abroga...
Objectives: Over the past few years, ruthenium has been under attention for development of organomet...
<p>Fig 7A. Images represent the change in capillary width induced by 10 ng/ml rBmAsnRS and 10 ng/ml ...
Objective: An integrated analysis was undertaken to characterize the antitumor activity and safet...
Contains fulltext : 81190.pdf (publisher's version ) (Closed access)Angiogenesis, ...